ONCIN Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.…
Industry Peers
BiotechnologyKey Statistics
About Oncoinvent (OSL: ONCIN)
›
Oncoinvent (OSL: ONCIN) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 42 employees.
The shares were at 73.00 NOK on 19 November 2026, up 14.1% over 52 weeks. Its 52-week range is 40.10 NOK to 144.00 NOK: the price is 49.3% below the high and 82.0% above the low.
Its market capitalisation is 447.37M NOK.
Oncoinvent reports return on equity of -106.0% and revenue down 31.4% year over year.
It holds more cash than debt, a net cash position of 104.74M NOK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 111.00 NOK is 52.1% above the current price. The next earnings report is expected on 25 February 2027.